/
CTSO
$0.38+$0.02 (+5.44%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$22.7M
63M shares
52-week range
$0.35 – $1.30
3% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Borrow rate
0.81%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-7.17
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $20.3M | $22.8M | $39.5M | $40.1M | $34.7M | $31.1M | $35.6M | $37.1M |
| Cost of revenue | $7.5M | $7.4M | $11.1M | $11.0M | $14.0M | $9.1M | $10.7M | $10.6M |
| Gross profit | $12.8M | $15.4M | $28.4M | $29.1M | $20.7M | $22.0M | $24.9M | $26.5M |
| Gross margin | 63.0% | 67.7% | 72.0% | 72.5% | 59.8% | 70.6% | 69.9% | 71.5% |
| R&D | $7.7M | $12.1M | $8.8M | $16.4M | $15.1M | $15.6M | $7.6M | $5.1M |
| Operating income | −$15.6M | −$19.0M | −$10.4M | −$22.7M | −$31.5M | −$31.9M | −$16.5M | −$14.2M |
| EBITDA | −$16.0M | −$18.7M | −$9.7M | −$24.2M | −$30.0M | −$27.9M | −$19.3M | −$4.4M |
| Net income | −$17.2M | −$19.3M | −$7.8M | −$24.6M | −$32.8M | −$29.2M | −$20.7M | −$8.2M |
| Net margin | -85.0% | -84.6% | -19.9% | -61.2% | -94.6% | -94.1% | -58.2% | -22.1% |
| EPS (diluted) | -0.56 | -0.60 | -0.20 | -0.57 | -0.75 | -0.65 | -0.38 | -0.13 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $39M | $-0.17 | $-0.18–$-0.15 | 2 |
| 2027 | $47M | $0.03 | $0.03–$0.03 | 1 |
| 2028 | $52M | $0.06 | $0.06–$0.06 | 1 |
| 2029 | $54M | $0.08 | $0.08–$0.08 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Cytosorbents Corp.
CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.
www.cytosorbents.com- Employees
- 129
- IPO / List date
- May 17, 2005
- HQ
- PRINCETON, NJ
Held by traders on TradeandTell
No one on the platform currently holds CTSO.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 100,720 | $57.0K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2014-12-05 | 1-for-25reverse |
| 2006-06-28 | 1-for-5.8reverse |
Recent trades on TradeandTell
No one on the platform has traded CTSO yet.
